Markets
Cardiol Therapeutics Inc. (CRDL)
CRDLNASDAQ-CMBiotechnology: Biological Products (No Diagnostic Substances)
$0.9801
+0.0083 (+0.85%) today
At the close, Nov 18, 4:00 PM ET. After hours $0.9900 +4.20%
+0.85% 1D
- Market cap
- $121.32m
- P/E
- –
- EPS, last 4 quarters
- $-0.2400
- Dividend yield
- –
- Day range
- $0.9300 to $0.9900
- 52-week range
- $0.8800 to $2.34
- Average volume
- –
- Previous close
- $0.9718
Analysts
3 coveringBuy3 buy, 0 hold, 0 sell
Targets a year out average $10.00, +920.3% from here
$9.00now $0.9801$11.00
Earnings
next estimate $-0.0500Next report
Dec 2025
+44.4%
Mar 2026
0.0%
Jun 2026
+55.6%
Sep 2026
-33.3%
estimate reported, and the surprise
Financials
No quarterly figures from the source.
News
8 latest- 5 Small Drug Stocks Poised to Benefit From a Biotech RecoveryZacks · Sep 14, 2026
- Is Aspen Pharmacare (APNHY) Outperforming Other Medical Stocks This Year?Zacks · Sep 10, 2026
- Biotech Stocks At 52-Week Highs - CRDL, NEO, SPTX, RAPP, CGEM RTTNews · Aug 27, 2026
- Biotech Stocks At 52-Week Highs - GENB +15%, BDSX +10%, CDNA +6%, CPIX +10%, CRDL +7% RTTNews · Aug 26, 2026
- Is Cardiol Therapeutics (CRDL) Stock Outpacing Its Medical Peers This Year?Zacks · Aug 25, 2026
- Cardiol Therapeutics Inc. (CRDL) is a Great Momentum Stock: Should You Buy?Zacks · Aug 24, 2026
- Cardiol Therapeutics Advances CardiolRx in Pivotal Phase III Pericarditis TrialMarketBeat · Aug 12, 2026
- Pharming Group Gears Up to Report Q4 Earnings: What's in the Cards?Zacks · Mar 3, 2026
The company
Cardiol Therapeutics Inc. is a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ-CM
- Region
- North America
- Website
- cardiolrx.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.